These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

566 related items for PubMed ID: 16690760

  • 1. Interleukin-6 signalling in juvenile idiopathic arthritis is limited by proteolytically cleaved soluble interleukin-6 receptor.
    Peake NJ, Khawaja K, Myers A, Nowell MA, Jones SA, Rowan AD, Cawston TE, Foster HE.
    Rheumatology (Oxford); 2006 Dec; 45(12):1485-9. PubMed ID: 16690760
    [Abstract] [Full Text] [Related]

  • 2. Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies.
    Usón J, Balsa A, Pascual-Salcedo D, Cabezas JA, Gonzalez-Tarrio JM, Martín-Mola E, Fontan G.
    J Rheumatol; 1997 Nov; 24(11):2069-75. PubMed ID: 9375862
    [Abstract] [Full Text] [Related]

  • 3. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation.
    Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, Yamaguchi A, Kishimoto T, Suda T, Kashiwazaki S.
    J Bone Miner Res; 1996 Jan; 11(1):88-95. PubMed ID: 8770701
    [Abstract] [Full Text] [Related]

  • 4. Elevated concentrations of monocyte derived cytokines in synovial fluid of children with enthesitis related arthritis and polyarticular types of juvenile idiopathic arthritis.
    Saxena N, Aggarwal A, Misra R.
    J Rheumatol; 2005 Jul; 32(7):1349-53. PubMed ID: 15996076
    [Abstract] [Full Text] [Related]

  • 5. Interleukin-6, soluble interleukin-2-receptor and soluble interleukin-6-receptor in sera of patients with rheumatoid arthritis: influences of disease activity and drug therapy.
    Franke S, Herrmann D, Hein G, Müller A, Stein G.
    Eur J Med Res; 1997 Sep 29; 2(9):401-6. PubMed ID: 9300938
    [Abstract] [Full Text] [Related]

  • 6. Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid.
    Desgeorges A, Gabay C, Silacci P, Novick D, Roux-Lombard P, Grau G, Dayer JM, Vischer T, Guerne PA.
    J Rheumatol; 1997 Aug 29; 24(8):1510-6. PubMed ID: 9263143
    [Abstract] [Full Text] [Related]

  • 7. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
    Urbańska-Ryś H, Wiersbowska A, Stepień H, Robak T.
    Eur Cytokine Netw; 2000 Sep 29; 11(3):443-51. PubMed ID: 11022130
    [Abstract] [Full Text] [Related]

  • 8. Levels of matrix metalloproteinase (MMP)-1 in paired sera and synovial fluids of juvenile idiopathic arthritis patients: relationship to inflammatory activity, MMP-3 and tissue inhibitor of metalloproteinases-1 in a longitudinal study.
    Peake NJ, Khawaja K, Myers A, Jones D, Cawston TE, Rowan AD, Foster HE.
    Rheumatology (Oxford); 2005 Nov 29; 44(11):1383-9. PubMed ID: 16049050
    [Abstract] [Full Text] [Related]

  • 9. Soluble interleukin 6 receptor: A novel marker of moderate to severe sleep-related breathing disorder.
    Mehra R, Storfer-Isser A, Kirchner HL, Johnson N, Jenny N, Tracy RP, Redline S.
    Arch Intern Med; 2006 Sep 18; 166(16):1725-31. PubMed ID: 16983050
    [Abstract] [Full Text] [Related]

  • 10. Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis.
    Lotito AP, Campa A, Silva CA, Kiss MH, Mello SB.
    J Rheumatol; 2007 Apr 18; 34(4):823-30. PubMed ID: 17343316
    [Abstract] [Full Text] [Related]

  • 11. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis.
    Hasegawa M, Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K.
    J Rheumatol; 1998 Feb 18; 25(2):308-13. PubMed ID: 9489824
    [Abstract] [Full Text] [Related]

  • 12. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
    Rose-John S, Scheller J, Elson G, Jones SA.
    J Leukoc Biol; 2006 Aug 18; 80(2):227-36. PubMed ID: 16707558
    [Abstract] [Full Text] [Related]

  • 13. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis.
    De Benedetti F, Massa M, Pignatti P, Albani S, Novick D, Martini A.
    J Clin Invest; 1994 May 18; 93(5):2114-9. PubMed ID: 8182142
    [Abstract] [Full Text] [Related]

  • 14. IL-6 and sIL-6R concentration in the cerebrospinal fluid and serum of MS patients.
    Stelmasiak Z, Kozioł-Montewka M, Dobosz B, Rejdak K.
    Med Sci Monit; 2001 May 18; 7(5):914-8. PubMed ID: 11535934
    [Abstract] [Full Text] [Related]

  • 15. Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease. Results of a pilot study.
    Bagli M, Papassotiropoulos A, Hampel H, Becker K, Jessen F, Bürger K, Ptok U, Rao ML, Möller HJ, Maier W, Heun R.
    Eur Arch Psychiatry Clin Neurosci; 2003 Feb 18; 253(1):44-8. PubMed ID: 12664314
    [Abstract] [Full Text] [Related]

  • 16. Nitric oxide-derived species in synovial fluid from patients with juvenile idiopathic arthritis.
    Lotito AP, Muscará MN, Kiss MH, Teixeira SA, Novaes GS, Laurindo IM, Silva CA, Mello SB.
    J Rheumatol; 2004 May 18; 31(5):992-7. PubMed ID: 15124263
    [Abstract] [Full Text] [Related]

  • 17. Interleukin-6 trans-signalling in chronic inflammation and cancer.
    Scheller J, Ohnesorge N, Rose-John S.
    Scand J Immunol; 2006 May 18; 63(5):321-9. PubMed ID: 16640655
    [Abstract] [Full Text] [Related]

  • 18. [Soluble interleukin-6 receptors in the serum in multiple myeloma].
    Scudla V, Kubalová D, Bacovský J, Lukes J, Vavrdová V.
    Cas Lek Cesk; 1996 Nov 20; 135(22):719-22. PubMed ID: 8998823
    [Abstract] [Full Text] [Related]

  • 19. Soluble IL-6 receptors (sIL-6R) in hematological patients receiving immunotherapy with IL-2/IFN-alpha or donor lymphocytes following bone marrow transplantation.
    Toren A, Novick D, Ackerstein A, Or R, Slavin S, Nagler A.
    Bone Marrow Transplant; 1996 Oct 20; 18(4):721-4. PubMed ID: 8899186
    [Abstract] [Full Text] [Related]

  • 20. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses.
    Müller-Newen G, Küster A, Hemmann U, Keul R, Horsten U, Martens A, Graeve L, Wijdenes J, Heinrich PC.
    J Immunol; 1998 Dec 01; 161(11):6347-55. PubMed ID: 9834125
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.